Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584562 | 0.79 | NUDT1 (0.42) | JAK1 | |
| SCHEMBL3593111 | 0.78 | — | — | |
| SCHEMBL3587025 | 0.76 | — | — | |
| SCHEMBL3587598 | 0.75 | JAK2 (0.46) | — | |
| SCHEMBL3589649 | 0.75 | NUDT1 (0.40) | — | |
| SCHEMBL182833 | 0.69 | DHFR (0.36) | — | |
| SCHEMBL3590110 | 0.69 | MEN1 (0.30) | — | |
| SCHEMBL183205 | 0.69 | DHFR (0.37) | — | |
| SCHEMBL4818205 | 0.65 | HTT (0.34) | — | |
| SCHEMBL7698086 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771362-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-26 | — | — | US | disclosed |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-09 | — | — | US | disclosed |
| US-9394301-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-09-03 | — | — | US | disclosed |
| US-9012633-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-8431596-B2 | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2217578-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009047514-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246915-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885 |
| US-20100298339-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885 |
| US-20140155594-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885 |
| US-20170066762-A1 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use | AXL, TYRO3, FLT3 | JAK1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.